Published by Alexander Bueso on 23rd December 2019
(Sharecast News) - Switzerland's Roche has bought the rights to launch and sell one of Sarepta Therapeutics's gene therapy treatments for Duchenne muscular dystrophy outside of the States, sending shares in the US-based biotechnology outfit flying in premarket trading.